Surrogate end points for long-term outcomes in chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2103-2111

  Akwaa, Frank ^a   Liesveld, Jane ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

BCR ABL inhibitors; CML CP; Landmark; Response; Survival

Indexed keywords

BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; PONATINIB;

CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DISEASE MARKER; DRUG EFFICACY; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884497439     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.772607     Document Type: Review

References (68)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
2. Quint ás-Cardama A, Cortes JE. Molecular biology of bcr-abl1 positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630.
3. Quint ás-Cardama A, Cortes JE. Chronic myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc 2006; 81: 973-988.
4. Goldman J. ABC of clinical haematology: Chronic myeloid leukaemia. Br Med J 1997; 314: 657-660.
5. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051.
6. National Comprehensive Cancer Network (NCCN). Chronic myelogenous leukemia V.1. 2013. NCCN Clinical Practice Guidelines in Oncology. Available from: Http://www.nccn.org/professionals/physician+gls/pdf/cml.pdf
7. Novartis Pharmaceuticals Corporation. Gleevec (imatinib) package insert. 2012. East Hanover, N.J.
8. Bristol-Myers Squibb Company. Sprycel (dasatinib) package insert. 2011. Princeton, N.J.
9. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) package insert. 2012. East Hanover, N.J.
10. Pfizer, Inc. Bosulif (bosutinib) package insert. 2012. New York, N.Y.
11. Ariad Pharmaceuticals Inc. Iclusig (ponatinib) package insert. 2012. Cambridge, M.A.
12. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict se ns itivity criteria. Clin Cancer Res 2007; 13: 7080-7085.
13. O'B rien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
14. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
15. Deininger M, O'B rien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: Abstract 1126.
16. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
17. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-1129.
18. Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95: 232-240.
19. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
20. Kantarjian HM, Giles FJ, Bhalla KN, et al. N ilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117: 1141-1145.
21. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212.
22. Kantarjian H, O'Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 2011; 29: 3173-3178.
23. Colburn WA. Optimizing the use of biomarkers, surrogate end points, and clinical end points for more efficient drug development. J Clin Pharmacol 2000; 40: 1419-1427.
24. Fleming TR. Surrogate end points and FDA' s accelerated approval process. Health Aff(Millwood) 2005; 24: 67-78.
25. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate end points: A basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
26. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002; 2: 19-27.
27. McCain JA Jr. The ongoing evolution of end points in oncology. Manag Care 2010; 19: 1-11.
28. Food and Drug Administration. Code of Federal Regulations Title 21, Vol. 5, Subchapter D. Part 314-Applications for FDA Approval to Market a New Drug. Subpart H-Accelerated Approval of New Drugs for Serious or Life-Th reatening Illnesses. Sec. 314.510 Approval based on a surrogate end point or on an effect on a clinical end point other than survival or irreversible morbidity. 2010. Available from: Http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch. cfm?fr 314.510
29. Park JW, Kerbel RS, KelloffGJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004; 10: 3885-3896.
30. Motl S, Miller SJ, Burns P. Programs established by FDA to expedite patient access to medications. Am J Health Syst Pharm 2003; 60: 339-345.
31. Radich JP, Oehler V. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J Natl Compr Canc Netw 2007; 5: 497-504.
32. Management of chronic myeloid leukemia (CML): Recommendations from the European LeukemiaNet (ELN). Updated Pocketcard 2010. The European LeukemiaNet. Available from: Http://www. leukemia-net.org/content/leukemias/cml/ recommendations.
33. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast phase: Results of a phase 2 study. Blood 2002; 99: 3530-3539.
34. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99: 1928-1937.
35. Cortes J, Kim D-W, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-2183.
36. Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009; 94: 205-212.
37. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica 2008; 93: 1792-1796.
38. Apperley JF, Cortes JE, Kim D-W, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: The START-A trial. J Clin Oncol 2009; 27: 3472-3479.
39. Kantarjian H, Cortes J, Kim D-W, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113: 6322-6329.
40. Giles FJ, Abruzzese E, Rosti G, et al. N ilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010; 24: 1299-1301.
41. Giles FJ, Kantarjian H, le Coutre PD, et al. Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. J Clin Oncol 2010; 28: Abstract 6510.
42. Saglio G, Hochhaus A, Tee Goh Y, et al. Dasatinib in imatinibresistant or -intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study. Cancer 2010; 116: 3852-3861.
43. Anderson JR, Cain KC, Gelber RD. A nalysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
44. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the international randomized study of interferon and STI571 (IRIS). Blood 2010; 116: 3758-3765.
45. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa- 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-229.
46. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-1041.
47. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26; 3358-3363.
48. Palandri F, Iacobucci I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML. J Clin Oncol 2008; 26: 106-111.
49. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
50. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437-4444.
51. Rea D, Vellenga E, Junghanss C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib. Haematologica 2012; 97: Abstract 0199.
52. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112: 516-518.
53. Jabbour E, Kantarjian H, Shan J, et al. The achievement of a 3-month complete cytogenetic response (3-mo CCyR) to second generation (2nd) tyrosine kinase inhibitors (TKI) post imatinib failure is the only predictive factor for event-free (EFS) and overall survival (OS). Blood 2010; 116: Abstract 2289.
54. Giles FJ, l e Coutre PD, Pinilla-Ibarz J, et al. N ilotinib in imatinibresistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27: 107-112.
55. Breccia B, Orlandi SM, Latagliata R, et al. Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: A ' grey zone ' at 3, 6, and 12 months identifies chronic myeloid leukaemia patients who need early intervention. Br J Haematol 2011; 152: 108-121.
56. Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukemia. Curr Opin Hematol 2010; 17: 1-7.
57. Yeung T, Osborn P, White L, et al. CML patients failing to achieve MMR by 12 months may benefit from dose escalation or switching to nilotinib: A 24-month update of results from the TIDEL-II trial. Haematologica 2011; 96: 55.
58. White DL, Saunders V, Frede A, et al. Early switching from imatinib to nilotinib in CML patients failing to achieve early molecular targets may not be an effective approach in patients with very low OCT-1 activity: A TIDEL II sub-study. Blood 2010; 116: Abstract 356.
59. Miller C, Ailawadhi S, Millella AP, et al. Patients (pts) with Ph + chronic myeloid leukemia in chronic phase (CML-CP) with a suboptimal molecular response to imatinib (IM) can achieve deeper responses when switched to nilotinib. Blood 2010; 116: Abstract 950.
60. Lim S, Holdridge RC, Talpaz M, et al. Multicenter, single-arm phase II study of nilotinib in Philadelphia chromosome-positive (Ph + ) chronic myeloid leukemia in chronic-phase (CML-CP) patients with low imatinib trough plasma concentrations. J Clin Oncol 2011; 29: Abstract TPS202.
61. Quint ás-Cardama A, Cortes JE, O'Brien et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009; 115: 2912-2921.
62. Hanfstein B, M ü ller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096-2102.
63. Hochhaus M arin D, Ibrahim AR, Lucas C, et al. A ssessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238.
64. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
65. A, Saglio G, Chuah C, et al. Dasatinib and imatinibinduced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Analysis of molecular response kinetics in the DASISION trial. Blood 2011; 118: Abstract 2767.
66. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
67. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year followup. Leukemia 2012; 26: 2197-2203.
68. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 2012; 30: 3486-3492.